Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

ZURICH, Jan. 17, 2022  Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ (RTM™) technology platform, a unique antibody drug creation approach.

In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTM™ technology platform. In the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from the collaboration. Ono will pay to Neurimmune an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

"We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines," said Jan Grimm, CSO of Neurimmune. "The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology."

"We extremely appreciate Neurimmune's RTM™ technology platform as an excellent antibody creation technology through our drug discovery projects." said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. "Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases."

About Neurimmune

Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.

www.neurimmune.com

For additional information, please contact:

Neurimmune:
Dr. Fabian Buller, +41 44 755 4623
CBO of Neurimmune
[email protected]

Media:
Martin Meier-Pfister, +41 43 244 81 40
IRF
[email protected]

SOURCE Neurimmune